fda ind, page-45

Donman, personally I never found wishing and hoping to be a sound management strategy but each to their own.

Perhaps you could explain who "they" are and "what" they will be pay for? And if "they" would be prepared to "pay whatever to get it", why have "they" not signed a partnering agreement already, as is the case with our competitors.

If the "what" is the core patent underpinning "the technology (which) can be used to deliver a cure as well as treatment for many chronic and life-threatening diseases", well why would "they" pay "whatever" for this when the patent expires in 2018 and so few treatments will be commercialised by then?

If the "what" is TT-034 after a Pl/lla trail, then what market share will determine that "they" will pay "whatever" for it? The new drugs that have just hit the market, in my view, make this estimating this figure almost impossible because they are new and their effect on the market is yet to be seen. So are you saying "they" will pay "whatever" for something that "they" cannot determine when "they" will get a return on investment? If so, you saying "they" are managing their company on wishing and hoping as well. In my experience, companies that can afford to pay "whatever" do not use wishing and hoping as a business strategy.

If the "what" is a later stage TT-034, then explain how we are going to take its development passed the current stage when we have no money to do so?

Put some substance to your argument so we can all see you are more than just a slogan.